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was maintained as long as the effect metric used for Cox 
regression had a linear correlation with the true effect 
metric of at least 0.50. The conclusions held if the trial 
cohort consisted of an expected high benefit population (22% 
reduced sample size), but the effect was even stronger if the 
cohort was a population with modest expected benefit (31% 
reduced sample size). 
 
 
 
Conclusion: We have demonstrated that the required patient 
sample size for randomized trials in radiation oncology may 
be considerably reduced by taking heterogeneous dose-effect 
into account. Dual planning provides support for the 
statistical outcome modelling that increases trial power even 
if the dose-response model is moderately misspecified. The 
outcome of a trial in the example studied would be a 
randomized measure of 'benefit per Gy ∆MLD' with confidence 
interval. 
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Purpose or Objective: Gastrointestinal (GI) toxicity is a side-
effect induced by whole pelvis intensity modulated 
radiotherapy (WP-IMRT), affecting importantly patients’ 
quality of life. The aim of this study was to identify 
predictors of diarrhea in a cohort of chemo-naÏf patients 
treated with WP-IMRT after prostatectomy. 
 
Material and Methods: The Inflammatory Bowel Disease 
questionnaire (IBDQ) was used to assess the degree of GI 
symptoms after WP-IMRT, investigating 4 distinct areas: 
bowel and systemic symptoms, emotional and social 
functions. This study focused on the most clinically relevant 
item 5 relative to the bowel domain, in order to evaluate the 
frequency of liquid defecation. Patient-reported scores at 
baseline, at RT mid-point and end, and every 3 months after 
RT end were prospectively collected . The responses are 
scored on a 7-point scale where 7 corresponds to the best 
function and 1 to the worst. Clinical/dosimetric data in 115 
patients treated with adjuvant (n=65) or salvage (n=50) WPRT 
in a single Institute were available (static field IMRT:19; 
VMAT:55; Tomotherapy:41). Dose–volume histograms (DVHs) 
for intestinal loops and sigmoid colon were calculated. The 
25th percentile of the score variation between baseline and 
half/end RT was considered as end-point (∆ -IBDQ5≤-3). 
Associations between diarrhea and clinical/DVH parameters 
were assessed by logistic uni- and backward multi-variable 
analyses. A previously introduced method based on DVH 
differences between patients with/without diarrhea toxicity 
was used to select the most discriminative DVH parameters. 
 
Results: No significant correlation emerged for sigmoid 
colon, then the analysis was focused on intestinal loops. 
Patients without basal score and with ∆ -IBDQ5≤-3 were 
excluded from the analysis: 23/77 pts showed acute GI 
toxicity. At univariate analysis, volumes receiving 5 to 40Gy 
(V5-V40) were correlated with ∆ -IBDQ5≤- 3 (p<0.03). 
Multivariate analysis confirmed a leading role of dosimetric 
variables, while no significant correlation for clinical 
parameters was found. Best cut-off values (assessed by ROC) 
discriminating patients with/without ∆ -IBDQ5≤-3 were: 
V20<250cc, V30<150cc and V40<90cc. The overall incidence 
equal to 10% and 50% resulted for the group of patients with 
DVH parameters lower/higher than thresholds, respectively 
(p=0.0028, OR=4.9, AUC=0.68).  
 
 
 
Conclusion: Low-medium IMRT doses to intestinal loops were 
correlated to diarrhea symptom at half/end of RT. This study 
proposed new dose volume constraints, that may be used to 
prevent much radiation-induced GI morbidity. 
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Purpose or Objective: MRI-based focal tumour boosting is 
currently under clinical investigation for prostate cancer 
patients, e.g. in the FLAME trial. These highly conformal, 
focal dose distributions can be difficult to achieve with 
photons, depending on the size and location of the boost 
volume (i.e. proximity to critical organs at risk). Selected 
patients might therefore be candidates for proton therapy. In 
previous work we have established an MRI-based tumour 
control probability (TCP) model. Combined with published 
rectum and bladder normal tissue complication probability 
(NTCP) models we have in this study explored the use of 
biological (TCP and NTCP) models to identify prostate cancer 
patients that might be suitable candidates for proton therapy 
if treated according to FLAME-like trial protocols. 
 
Material and Methods: CT scans of seven patients from a 
prospective trial in our institution were used for planning. To 
obtain realistic boost geometries, MRI-based index tumours 
from a different cohort were used (matched on prostate 
volume), propagated with rigid registration on the prostate 
volume. VMAT plans (Eclipse, Varian Medical Systems) with 
and without a boost to the index lesion (95 Gy / 35 fx) were 
created; both plans delivered a conventional dose (77 Gy / 35 
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fx) to the non-involved prostate. Planning constraints used 
were based on institutional procedures as well as from the 
FLAME trial, with small modifications in the boost plans. The 
dose distributions (with/without boost) were used to 
calculate the TCP and NTCP values for each patient. The TCP 
model used apparent diffusion coefficient maps to estimate 
cell densities while the NTCP models used were the 
conventional Lyman model for the rectum (late rectal 
bleeding grade >= 2; Rad. Onc, 73, 21-32, 2004) and the 
Poisson LQ model for the bladder (contracture; Ågren PhD 
thesis, 1995). 
 
Results: The TCP increased from a median (range) of 0.45 
(0.08-0.83) with the conventional approach to 1.0 (no range) 
with the focal boost. While there were only minor differences 
in the rectum NTCPs with vs. without the boost there were 
considerable differences in the NTCP for the bladder for two 
of the patients (more than a doubling of the NTCP with the 
boost; Table 1). These two patients had the index lesion that 
was closest to the bladder. 
 
 
 
 
 
Conclusion: We have established a biological modelling 
based method to identify prostate cancer patients where the 
focal boost cannot be achieved with state of the art photon-
based treatment without a considerable increase in the 
NTCPs. Further work will consider the feasibility of proton 
planning, given both inter- and intra-fractional organ motion 
patterns.  
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Purpose or Objective: This study presents a universally 
applicable decision support system (DSS), with respect to the 
prediction of five-year biological no evidence of disease (5y-
bNED) for localised prostate cancer (PCa) patients treated by 
external beam radiation therapy (EBRT). 
 
Material and Methods: To develop a DSS this study utilised 
the traditional approach of model training based upon meta-
analysis data (MAD: n=5218) from the literature with model 
validation based upon routine clinical care data (CCD: n=827) 
from clinics with a rapid learning healthcare (RLHC) 
environment. The following standard clinical features for PCa 
patients were investigated to train and validate a tumour 
control probability model (TCP) and a predictive machine 
learning model (PML): primary tumour stage (T), lymph node 
stage (N), metastasis stage (M), prostate specific antigen 
(PSA), Gleason score (GS), clinical-target-volume (CTV), total 
dose (D), and fractional dose (d). These features were 
selected as they are typically known within all clinics treating 
PCa patients, thus maximising the generalizability of the DSS. 
 
Results: The DSS is comprised of two distinct models. The 
TCP model was found to be well calibrated with poor 
discriminative ability. Training resulted in an adjusted 
weighted R2 value of 0.76, a weighted mean absolute 
residual (wMAR) of 4.7% and an area under the curve (AUC) of 
0.67 [0.65, 0.69]. Validation resulted in an adjusted weighted 
R2 value of 0.51, a wMAR of 2.0% and an AUC of 0.57 [0.51, 
0.63]. Contrastingly, the PML model was found to be poorly 
calibrated with good discriminative ability. Training resulted 
in an adjusted weighted R2 value of 0.27, a wMAR of 8.3% 
and an AUC of 0.66 [0.64, 0.68]. Validation resulted in an 
adjusted weighted R2 value of 0.90, a wMAR of 16.2% and an 
AUC of 0.61 [0.56, 0.65]. Subset analysis shows that the DSS 
performs best in high-risk PCa patients with validation 
resulting in an AUC of 0.66 [60, 0.72] with a wMAR of 1.0%. 
 
Conclusion: A DSS developed with MAD has been validated in 
CCD extracted using RLHC infrastructure. The DSS uses 
standard clinical features to estimate with good accuracy 
(wMAR < 4.7%) and reasonable fidelity (AUC > 0.61) the 5y-
bNED rate and classification, respectively, of PCa patients. 
The performance of the DSS in the validation high-risk PCa 
cohort (wMAR = 1%) and patients (AUC = 0.66) for whom 
therapy could be potentially adapted or individualised based 
on the DSS has clinical relevance and should be prospectively 
validated. 
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Purpose or Objective: The use of biological information on 
tumour control and normal-tissue complications for 
treatment plan optimisation can be used for individualising 
the dose prescription. For patients with prostate cancer, 
moreover, the tumour localisation by means of MR-images 
facilitates the use of such information for a simultaneous 
dose escalation in the so-called dominant intraprostatic 
lesions (DIL), thus further improving the treatment outcomes. 
However, a correct modelling of the tumour-control 
